ABOUT US


Neopharmed Gentili is an Italian pharmaceutical company and is currently expanding internationally.
We specialize in bringing to market solutions of high therapeutic value, with the aim of helping people lead healthier and longer lives, as a result of our commitment across multiple therapeutic areas.

50

50+ years of experience in the field

10

Scientific knowhow in 10+ therapeutic areas

3M

3+ million patients treated in 2024

LATEST NEWS


10 September 2026

Neopharmed Gentili strengthens its European rare disease platform as operations consolidate under a single brand

Neopharmed Gentili, a European pharmaceutical company with Italian roots, announces the consolidation of its European rare disease operations under a single brand, with companies across different countries changing their names. This follows the acquisition, in October 2025, of the European commercial operations for ORLADEYO® (berotralstat) for the treatment of hereditary angioedema (HAE) from BioCryst Pharmaceuticals.

READ MORE

PRODUCTS


Improving people’s lives, no matter what stage of illness they are in. We strive to restore quality of life to those facing the challenges of a therapeutic journey. Care, precision, professionalism, and great expertise are the values that drive our research and goals.

DISCOVER OUR LINE OF MEDICATIONS

INVESTORS


Neopharmed Gentili is an Italian company that is rapidly expanding abroad. Thanks to a policy of acquiring the best active ingredients for the most demanding therapeutic pathways, it represents a particularly attractive investment asset.

READ MORE

HCP


Organized by therapeutic areas, in this section, accredited physicians can download all informational materials and specific updates related to each medicine distributed by Neopharmed Gentili.

READ ALL INFORMATION AND SERVICES